HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Does FTC Health Ads Guide Read Like Rulemaking, Ignore Court Decisions On Requiring RCTs?

Executive Summary

“I'm not sure they shouldn’t have done a notice of proposed rulemaking,” says attorney Claudia Lewis. From previous guidance, “the FTC has taken it a step in the different direction that you need robust scientific evidence, in their mind robust scientific evidence means clinical data.”

You may also be interested in...

Attorneys: FTC’s Interpretation Of Penalty Offense Authority Yet To Be Tested In Court

Attorneys are closely watching how the US Federal Trade Commission’s latest wave of penalty offense notices to almost 700 companies plays out, noting – as did recently departed commissioner Christine Wilson – that seeking civil penalties in court under this “long dormant” authority could be challenging.

FTC’s Health Products Guidance: Attorneys Discuss Insistence On RCTs, Implications For Businesses

The updated and expanded guidance embodies the US Federal Trade Commission’s enforcement approach for more than a decade, identifying randomized clinical trials as the competent and reliable scientific evidence needed to back health-related claims. Attorneys from Kelley Drye & Warren, Lathrop GMP and Amin Talati Wasserman weigh in.

FTC Expands Dietary Supplement Advertising Guidance To All Products Making Health-Related Claims

The Federal Trade Commission’s Health Products Compliance Guidance, published 20 December, expands the agency’s focus from dietary supplements to all products making health-related claims, providing the first update in 25 years on the FTC’s thinking on clear and conspicuous disclosures and competent and reliable scientific evidence.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts